Harnessing the FBXW7 somatic mutant R465C for targeted protein degradation

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Targeted protein degradation (TPD) is a therapeutic strategy that leverages cellular machinery to eliminate specific proteins.
• Expanding the range of E3 ligases for proteasome-dependent TPD can broaden its therapeutic applications.
• Identifying novel E3 ligases, especially those specific to disease states, is crucial for advancing TPD.

Purpose of the Study:

• To investigate the potential of a specific somatic mutant of FBXW7 (R465C) for targeted protein degradation.
• To demonstrate the feasibility of using disease-specific mutant E3 ligases in TPD strategies.
• To explore new avenues for TPD by exploiting aberrant cellular components.

Main Methods:

• Utilized heterobifunctional compounds designed to recruit target proteins to the E3 ligase.
• Investigated the degradation of target proteins mediated by the FBXW7 R465C mutant.
• Employed proteasome-dependent degradation pathways.

Main Results:

• Successfully demonstrated that the FBXW7 R465C mutant can be exploited by heterobifunctional compounds for targeted protein degradation.
• Confirmed the degradation of specific proteins in the presence of the mutant E3 ligase.
• Validated the principle of using disease-exclusive mutant E3 ligases for TPD.

Conclusions:

• The FBXW7 R465C mutant is a viable E3 ligase for targeted protein degradation applications.
• Mutant E3 ligases present in diseased cells offer a promising strategy for developing targeted therapies.
• This approach expands the toolbox for TPD and holds potential for treating diseases characterized by specific E3 ligase mutations.